Abstract: A computer-implemented method of analysing nuclear magnetic resonance, NMR, data of a target object is provided. The method comprises receiving NMR data of the target object, and analysing the received NMR data using a model of the diffusive behaviour of particles within the target object. The model includes a time parameter and a space parameter, the time parameter describing temporal characteristics of the diffusive behaviour of particles in the model and the space parameter describing spatial characteristics of the diffusive behaviour of particles in the model. The model is constrained such that the value of the time parameter and the value of the space parameter are related according to a correlation function. An apparatus for analysing nuclear magnetic resonance, NMR, data of a target object is also provided.

Abstract: The disclosure concerns a method for the treatment of cervical dystonia, comprising inserting a stimulation device into the brain of a patient, the stimulation device being configured to provide electrical stimulation to affect first and second stimulation targets within the brain. The first stimulation target is the subthalamic nucleus (STN); and the second stimulation target is the ventral intermediate nucleus (VIM), or the ventralis oralis posterior thalamus (VOP), or both the ventral intermediate nucleus (VIM) and the ventralis oralis posterior thalamus (VOP).

Abstract: A computer-implemented method of analysing nuclear magnetic resonance, NMR, data of a target object is provided. The method comprises receiving NMR data of the target object, and analysing the received NMR data using a model of the diffusive behaviour of 5 particles within the target object. The model includes a time parameter and a space parameter, the time parameter describing temporal characteristics of the diffusive behaviour of particles in the model and the space parameter describing spatial characteristics of the diffusive behaviour of particles in the model. The model is constrained such that the value of the time parameter and the value of the space parameter 10 are related according to a correlation function. An apparatus for analysing nuclear magnetic resonance, NMR, data of a target object is also provided.

Abstract: The present invention relates to the treatment of osteoarthritis with certain gamma-aminobutyric acid derivatives. Patients to be treated include those having elevated pain sensitivity. Specific therapies disclosed include those in which the gam-ma-aminobutyricacid derivative is administered as a single active agent rather than in combination with another active agent.

Abstract: The present invention relates to the treatment of leukemia, (e.g. acute myeloid leukemia, AML) using a triple combination of: arsenic trioxide; iron; and an artemisinin, such as artesunate.

Abstract: The invention is in the field of growth of Mycobacteria. In particular, agents have been identified which enhance the growth of Mycobacterial species, which are naturally slow-growing. Such agents can therefore be used in the identification of Mycobacteria and in the diagnosis of Mycobacterial infections.

Abstract: The invention provides a method of treating mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) in a patient, comprising administering to the patient autologous erythrocytes that contain thymidine phosphorylase and are free of animal proteins other than proteins derived from the patient. The erythrocytes generally contain a low amount of endotoxin.

Abstract: Methods and apparatus for obtaining probability density functions representing expected distributions of values of a parameter associated with an imaging modality are disclosed. The probability density functions are derived using data obtained from reference tissue volumes using the same imaging modality and at least one other type of imaging modality. The probability density functions are used to analyze data obtained from a volume of tissue of a patient in order to classify the tissue according to tissue type. Methods and apparatus are also disclosed in which deviations from a mean of an arctangent of ratios of first and second metabolite intensities in voxels are used to identify tissue types.

Abstract: The invention is in the field of growth of Mycobacteria. In particular, agents have been identified which enhance the growth of Mycobacterial species, which are naturally slow-growing. Such agents can therefore be used in the identification of Mycobacteria and in the diagnosis of Mycobacterial infections.

Abstract: MRSA CC398 is a clone of S. aureus that has recently emerged in pigs and other domestic animals worldwide. As any other MRSA, the clone displays high levels of antibiotic resistance and poses a serious threat to human health because of the risk of antibiotic treatment failure in human patients. We developed a new diagnostic test for identification of MRSA CC398 using a single one-step PCR that is very easily performed within a few hours. The test is based on the principle that clonal differences within S. aureus are reflected in the sequence of a gene (sau1hsdS1) located on the chromosome of this bacterial species. Accordingly, such a gene represents an optimal target for S. aureus and MRSA identification at the clone level. The test includes detection of the gene conferring methicillin resistance (mecA), therefore allowing rapid discrimination between methicillin-susceptible and methicillin-resistant variants of the clone.

Abstract: The invention provides a method of treating mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) in a patient, comprising administering to the patient autologous erythrocytes that contain thymidine phosphorylase and are free of animal proteins other than proteins derived from the patient. The erythrocytes generally contain a low amount of endotoxin.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyruvamide compounds of the following formula (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyruvamide compounds of the following formula (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.

Abstract: The invention provides methods and compositions for the treatment of primary, metastatic, and residual cancer in mammals, and more particularly, the use of materials such as whole cells and derivatives and portions thereof to stimulate the immune system to attack cancer.

Abstract: The present invention pertains generally to the field of therapeutic compounds and more specifically to certain pyruvamide compounds of the formula (X) (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.

Abstract: The present invention relates to peptides which impair PBX-dependent regulation of gene transcription. In particular, the invention provides the use of a peptide comprising the amino acid sequence X1 X2 X3 W M X4 X5 X6 X7, wherein the sequence X1 to X7 is an amino acid sequence comprising at least 9 amino acids, which may optionally be interrupted by one or two amino acid residues between one or more of the 9 amino acid positions defined herein; X1 is selected from W, T, PE, KQI, VV, PQT, H, RI and absent; X2 is an amino acid with an aromatic side chain; X3 is P or D; X4 is an amino acid with a basic side chain; X5 is an amino acid with a charged side chain; X6 is an amino acid with a charged side chain; and X7 is an amino acid with a basic side chain or Serine; in the manufacture of a medicament for treating or preventing a disorder in which aberrant cell division occurs.

Abstract: Combinations of cell lines are provided for allogeneic immunotherapy agents in the treatment of cancer. Cancer vaccines generally have been limited to the use of cells that contain at least some tumour specific antigens (“TSAs”) and/or tumour associated antigens (“TAAs”) having shared identity with antigens in a targeted tumour. In such cases, tumour cells often are utilised as a starting point on the premise that only tumour cells will contain TSAs or TAAs or relevance, and the tissue origins of the cells are matched to the tumour site in patients. A primary aspect of the invention is the use of immortalised normal, non-malignant cells, in combination with primary and/or metastatic tumour cells, as the basis of an allogeneic cell cancer vaccine. Normal cells do not posses TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines when administered in combination with primary and/or metastatic tumour cells.

Abstract: The invention provides a nucleotide sequence representing a pathogenicity island found in species of pathogenic mycobacteria. The islands are shown as SEQ ID NOS: 3 and 4 and comprises several open reading frames encoding polypeptides. These polypeptides and their use in diagnosis and therapy form a further aspect of the invention.

Abstract: Combinations of cell lines are provided for allogeneic immunotherapy agents in the treatment of cancer. Cancer vaccines generally have been limited to the use of cells that contain at least some tumour specific antigens (“TSAs”) and/or tumour associated antigens (“TAAs”) having shared identity with antigens in a targeted tumour. In such cases, tumour cells often are utilised as a starting point on the premise that only tumour cells will contain TSAs or TAAs or relevance, and the tissue origins of the cells are matched to the tumour site in patients. A primary aspect of the invention is the use of immortalised normal, non-malignant cells, in combination with primary and/or metastatic tumour cells, as the basis of an allogeneic cell cancer vaccine. Normal cells do not posses TSAs or relevant concentrations of TAAs and hence it is surprising that normal cells are effective as anti-cancer vaccines when administered in combination with primary and/or metastatic tumour cells.

Abstract: The invention provides a nucleotide sequence representing a pathogenicity island found in species of pathogenic mycobacteria. The islands are shown as SEQ ID NOS: 3 and 4 and comprises several open reading frames encoding polypeptides. These polypeptides and their use in diagnosis and therapy form a further aspect of the invention.